Danaher Buys Beckman: Fixing Quality Issues, Cutting Costs Are Priorities
This article was originally published in The Gray Sheet
Executive SummaryDanaher’s priorities for its newly acquired Beckman Coulter diagnostics business will include cutting $250 million in costs, completing quality control fixes already underway and getting certain cardiac troponin assays back on the market.
You may also be interested in...
Clinical laboratories in the US and Europe are facing pressure from all sides as budget cuts and staffing shortages compete with a growing demand for ever-more-sophisticated lab tests to serve an aging population. As a result, lab directors are seeking innovative ways to improve efficiency and do more with less, and those goals are driving innovation in technology-based solutions such as laboratory automation and informatics. These solutions are increasingly becoming integrated into the total laboratory process – encompassing not only sample analysis, but also up- and downstream workflows – paving the way for the fully integrated, automated lab of the future.
Firm will combine IRIS International with its Beckman Coulter diagnostics unit. Deal adds leading worldwide provider of automated urine microscopy and chemistry systems, including IRIS’ fully-automated iQ bench-top analyzer for urine microscopy.
A report from PricewaterhouseCoopers suggests the in vitro diagnostics market will see accelerated growth next year due in part to a surge in companion diagnostics partnerships and M&A deals.